Condronyl IAL

Description
Sterile, biodegradable and isotonic injectable gel for intra-articular use.
Condronil IAL is composed of a medium molecular weight hyaluronic acid (1.0 - 1.5 x ^10⁶ Dalton), produced by the bacterium Streptococcus equi, formulated at a concentration of 16 mg/ml in a physiological buffer solution.
Condronil IAL is characterized by viscoelastic properties, therefore it helps to normalize the viscosity of the synovial fluid present in the intraarticular cavity.
Substitute for synovial fluid in joints affected by degenerative or mechanical arthropathy, which causes pain or reduced mobility.
It acts only at the level of the joint where it is injected, without exerting any systemic action.
Sterile product.

How to use
Remove any joint effusion before injecting Condronil IAL; the same needle should be used for removing the effusion and injecting Condronil IAL.
Remove the protective cap from the syringe, taking special care to avoid contact with the orifice. Gently grasp the needle guard and attach the needle to the Luer-lock fitting, screwing it firmly until you feel a slight back pressure to ensure a tight seal and prevent gel leakage during administration. The needle should be between 18 and 22 gauge.
Before injection, treat the injection site with a suitable disinfectant. Inject Condronil IAL using aseptic technique. Inject only into the joint cavity.
It is recommended to perform an initial cycle of three treatment sessions, one week apart, followed by maintenance sessions if necessary, according to medical prescription.

components
Sodium hyaluronate (16 mg/ml), sodium chloride, monosodium phosphate dihydrate, disodium phosphate dodecahydrate, water for injections

warnings
Indicated for intra-articular injections only and should only be dispensed by a physician who has received specific training in intra-articular injection technique.
Before use, check the integrity of the syringe and the expiration date.
Do not use needles other than those indicated.
The product should not be injected into an infected or severely inflamed joint. Injection should be avoided in cases of active infection or inflammatory skin conditions near the injection site.
Since there are no clinical data available on the use of hyaluronate in children, treatment with Condronil IAL in these cases is not recommended.
After the intra-articular injection, it is recommended that the patient avoid physical activities that are demanding on the joint and resume normal activities after a few days.
Condronil IAL is a single-use product; quality and sterility are only guaranteed if the syringe is sealed. Therefore, any residue should be discarded and not reused, even after resterilization.
Do not use the product if the packaging is already open or damaged.
The syringe with needle must be discarded immediately after use, even if the solution has not been completely administered. After use, dispose of it according to the regulations in force.
There are incompatibilities between sodium hyaluronate and quaternary ammonium compounds, such as benzalkonium chloride solutions. Therefore, avoid contact between Condronil IAL and these substances.
Following the injection of Condronil IAL, some transient side effects may occur, such as pain, stiffness, warmth, redness or swelling. These side effects can be relieved by applying ice to the treated joint. They usually disappear after a short time. If symptoms persist, consult a doctor. Any other unwanted side effects associated with the injection of Condronil IAL should be reported to your doctor.

Conservation
Store Condronil IAL at 2-25°C (36-77°F) in a dry place, in the original carton. Protect from light, heat and frost. Keep out of reach of children.
Shelf life in intact packaging: 36 months.

Format
2 ml pre-filled syringe